Announced Today The Release of Electronic Medical Record Software for Breast Cancer Patient

Robert Graham Reporting: Press Release New York City New York August 1, 2012

---

Announced Today The Release of Electronic Medical Record Software for Breast Cancer Patient.

---

GenNXeix Medical Software

---

Announced Today The Release of Electronic Medical Record Software for Breast Cancer P

atient. Use of electronic medical records (EMR) for Breast Cancer Oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data.

Being The 1st and only Breast Cancer EMR Software is a product our entire Team is happy that our work product is going to save breast cancer patients and extend their life. GenNXeix gloStream is the only EMR company that offers a 15-Day Money Back Success Guarantee. We guarantee that if we can't get you back to full patient load within 15 clinic days of implementing

Brought To You By gloStreamgloEMR, we'll provide a full refund for all GenNXeix gloStream software and services. With GenNXeix gloStream you can be confident that your EMR purchase will help your business succeed and won't cause it to falter. Doctors considering EMR software and thinking about whether they will qualify for stimulus funding must be certain that the systems they choose are certified and

stimulus ready. You can be confident that gloEMR from GenNXeix gloStream will qualify for stimulus funding because we guarantee it. In fact, GenNXeix gloStream will refund the software costs for any eligible professional who goes through our exclusive gloDNA process, and then finds themself unable to qualify as a meaningful user and acquire stimulus funding. The unique combination of GenNXeix gloStream certified software and our exclusive gloDNA process ensures that doctors always have the tools and knowledge needed to achieve truly meaningful use - today, and well into the future. Gennxeix after researching breast cancer to assess the utility of using EMR data in

population-based cancer research by comparing a database of EMRs from community oncology clinics against Surveillance Epidemiology and End Results (SEER) cancer registry data and two claims databases (Medicare and commercial claims). Demographic, clinical, and treatment patterns in the EMR, SEER, Medicare, and commercial claims data were compared using six tumor sites: breast, lung/bronchus, head/neck, colorectal, prostate, and non-Hodgkin’s lymphoma (NHL). We identified various challenges in data standardization and selection of appropriate statistical procedures. We describe the patient and clinic inclusion criteria, treatment definitions, and consideration of the administrative and clinical purposes of the EMR, registry, and claims data to address these challenges. Sex and 10-year age distributions of patient populations for each tumor site were generally similar across the data sets. We observed several differences in racial composition and treatment patterns, and modest differences in distribution of tumor site. We calculated treated proportions of patients by dividing the number of patients receiving ambulatory therapy by the total number of patients with the specific cancer diagnosis. Given the large sample sizes from the databases evaluated, traditional tests of significance resulted in statistically significant findings, even for small absolute differences. Therefore, we focused on descriptive comparisons and used Cohen’s w effect size (ES) with a pooled standard deviation to assess the importance of observed differences. This qualitative measure is not based on a rigorous hypothesis-testing framework and does not have a probabilistic interpretation such as a P-value obtained from standard methods. While the ES interpretation depends on the subject matter, Cohen classified the magnitude of the ES as small (w = ~0.1), medium (w = ~0.30), and large (w = ~0.50).25,26 A large proportion of data was missing for race (40%) and tumor stage (~70%) in the EMR records. The largest percentage of missing stage data (97%) was observed for NHL. Given that NHL treatment is determined mainly by subtype and pathology (not stage), this missing data trend was understandable. When these two categories were excluded, the proportion missing for stage was 63%. Text fields were not analyzed to determine whether they contained missing stage information. We selected a hot-deck method to impute missing data,27 and compared this method against two other regression-based imputation procedures.28–30 We also evaluated the model prediction properties of hot-deck imputation by applying it to records with known values. Sociodemographic information (2000 US Census) was incorporated into the imputation models. Pre- and post-imputation marginal distributions were compared to evaluate similarity in data sets and were found to be comparable to distributions of data among records with complete information for race and stage. An evaluation of the performance of the hot-deck procedure under a simple missing data mechanism that compared imputed and observed data was also conducted. Only post-imputed data comparisons are presented. SEER provided the largest number of patient records (331,427). There were 60,255 unique records in Medicare and 32,357 and 16,427 records in the EMR and commercial claims, respectively. Several differences were observed in overall tumor site distributions. Excluding the “other tumors” category, the largest proportion of patients had prostate cancer in Medicare, and the largest proportion of patients had breast cancer in the other three databases. In the oncology EMR data, >25% of the cancer patient records had breast tumors – nearly 7% more than the proportion in SEER – while Medicare had the lowest fraction (8%). The EMR had the highest percentage of lung cancer and NHL patients; proportions of patients with CRC or head/neck tumors were generally comparable across all databases. Prostate cancer was noticeably under-represented in the EMR, likely because prostate cancer patients are treated primarily by urologists.

Why is Houston Base Oil & Gas Not Invested In India BP British Petroleum is:

NYTimes And HybridMedical Media Reporting 7/25/2012 :

---

Why is Houston Base Oil & Gas Not Invested In India BP British Petroleum is:

---

Gennxeix Petroleum Cloud Base Software is leading with Business Intelligence and

Analytics For Oil & Gas Pipelines Security in Africa Makes It Possible For China & Houston Oil & Gas Companies to Invest in Project all of the world.

---

Hybrid Media A lunch time conversation with Gennxeix Petroleum Chief Information Officer Robert Graham Ph.D.

---

Is T Boone Pickens Right “The potential for natural gas as a transportation fuel and the impact it could have in freeing The United States from OPEC oil dependency “ ? Together, we have made America’s energy security a top ranking on the list of important

Brought To You By gloStream issues facing our great nation. And you — the 1.7 million members of the Pickens Plan army — have been the single most important element of that success.

---

Is The Chinese State-controlled CNOOC Right for buying Nexen from Canada? The last time a Chinese oil company announced an acquisition worth more than $10bn in

North America, it met with vehement political attacks from Washington that eventually forced the Chinese company to drop the bid. That failed deal – in which Cnooc’s $18.5bn offer for US oil group Unocal was very publicly rebuffed – was so scarring that it was years before Chinese oil companies dared to try to invest again in the US.

---

Is Africa What’s next in the upstream and downstream oil and gas business ? - Oil was discovered in Nigeria in 1956 at Oloibiri in the Niger Delta after half a century of exploration. The discovery was made by Houston base Shell-BP, at the time the sole concessionaire. Nigeria joined the ranks of oil producers in 1958 when its first oil field came on stream producing 5,100 barrels per day. Robert says yes the time is right the reason being is that Oil & Gas Companies has a new partner to secure their investment in exploration in Africa, India and even Canada. For a example GenNXeix®, Inc., we are a global Analytics Solution Provider, Enterprise content

enabler and Mobile Application Development company, announces a strategic partnership with IQGateway a world class, award winning, Business Intelligence Company that offers a complete Real Time Business Life Cycle Software Solution. IQGateway has selected the GenNXeix ™ solution to provide marketing Opt-in service to business intelligence customers. With offices in the United States and Europe, This service will allow business Intelligence customers to be pro active with business decision making process, with the use of the iQGateway real time business intelligence system. “We are pleased to partner with Hybrid GenNXeix says Krishna Kumar.” Director of iQ Gateway solution iQGateway Business 3.0, Management 3.0 and new technologies are rapidly forcing products and services into obsolescence causing market paradigms to be redefined. In this environment businesses have to stay ahead building sustainable value with focus on emerging markets, new customers, next generation products and unique services. It’s all about sensing, understanding and capitalizing in time. As specialists, iQG’s services offer insightful and simple winning solutions that are sensitive to client needs, helping them grow amidst the challenges of fast changing times. As the global economy evolves, we at iQG are focused on a conscious strategy of capital conservation, risk containment and efficiency improvement for our clients’, offering them healthy capital adequacy, sound liquidity and improved cost efficiencies. Enabling businesses to make the right investments with an aggressive strategic plan leading to operational excellence. While our engagements help automate decisions for operational efficiencies, some find it a discerning complex mix of math and statistics, analyzing variables, quantifying databases based on logic, yet analytics is a facilitator that can be applied in different ways, giving businesses the choice of applications that best work for them strategically. The incremental impact of analytics is fundamentally based on the value proposition that it offers, giving us at iQG reason enough to engage meaningfully with the business world around us. The growing ascendance of “structured healthcare” in developed & developing nations has brought about a renewed focus on the entire healthcare value chain. By definition, the structured healthcare market is an expansive Hybrid Gennxeix view of the provider( hospitals, clinics), payer(insurance and claims) and pharmaceutical and medical products sectors. A growing (but slow) reformation of the healthcare system within the OECD (Organization for Economic Co-operation & Development) countries is aimed to reduce the rate at which costs have been increasing while sustaining its current strengths. These reforms are not only critical to these nations as an economic indicator but also has a far more deepening impact on society at large. In majority of the OECD countries, healthcare accounts for a significant portion of their national GDP and employ a substantial workforce. Even a sliver of cost reduction has a far reaching impact on the overall cost efficiencies that can be achieved across the value chain. Healthcare in general has lagged behind other industries in improving operational performance and adopting technology-enabled process improvements. Spending on healthcare per person is on the rise albeit without any obvious evidence of better outcomes. More than ever at any point in time, the use and leverage of data along with the potential of predictive analytics, is an area that sees growing eminence amongst the measures deployed to yield better outcomes of spending. Most data in the healthcare domain is fragmented and lies in silos across hospitals (mainly clinical and patient data), claims data(insurance companies), pharmaceutical (including R & D data) and patient behavior (sentiment) data entities. Although the bigger opportunity lies in the integration of these data pools that could lead to huge benefits in overall process and cost efficiencies, at iQG, the macro level opportunities lie in dissecting the data that lies virgin and untapped within the current silo structures of data. By unleashing the full potential of predictive analytics and how it can be applied to these various pools of data, we at iQG believe, that the use of statistical algorithms on these data that can be transformed into actionable intelligence and can pave the way to non-holistic cost efficiencies across these data silos. USA – Texas Hybrid GenNXeix IQGateway -- ( http://iqgateway.com/) -- 300 Rayford Rd, #224,
Spring, Houston, Texas :77386
 or contact a sales representative at Ph: +1 2816616002
Email: info@iqgateway.com

Houston Texas 77027 Best Place in The World For Business ...Look Apple & Mircosoft Store Grand Opening

Robert Graham Reporting: Houston Texas Galleria

---

Houston Texas 77027 Best Place in The World For Business ...Look Apple & Mircosoft Store Grand Opening

---

---

---

---

---

---

---

---

Brought To You By Health Care Medicaid Debate Video

---

---

---

Not For Size For Substance “The Best NAACP Meeting In 103 Years” The Affordable Health Act

Not For Size For Substance “The Best NAACP Meeting In 103 Years” The Affordable Health Act NyTimes & Hybrid Medical Media spent this week at the 103rd Annual NAACP Meeting in Houston Texas to ask the question, Now that The Affordable Health Act has cleared the Supreme Court how will Affordable Heal act effect the people that support the NAACP. For the purpose of the article and easy math lest say that in 2010 there are one million Doctors offices in the USA and lest also say that there where two million patients that visited the one million Doctors offices. Now that the Affordable Act has

pass all cleared all of the hurdles. For the purpose of this article say we are now have six million patients and only one million Doctors Offices. What do we do? Genomics Science comes to the rescue. Genomics is a discipline in genetics concerned with the study of the genomes of organisms. The field includes efforts to determine the entire DNA sequence of organisms and fine-scale genetic mapping. NAACP Genomics is the next chapter for your community. Preventing diseases before they occurs says Rose Conrad Chief Executive Office of Gennxeix Biotech. Gennxeix Biotech

is base in Houston Texas in the Houston Medical Center. Rose goes on to say let’s uses Breast Cancer for and example. 18 % of Black Women will get Breast Cancer this year to 7% of white women. Now with the Affordable Care Act in place and genomic science those number are going to come down to all women getting breast cancer at 4% . Genomics science is making a major impact on breast cancer. 20% Of Breast Cancers are HER2 is over-expressed. HER2 Gene Amplified in Breast Cancer 82% Chance of Relapse. 34% chance of relapse. At The American Society of Clinical Oncology annual meeting in Chicago Roche announced the preliminary success of its antibody-drug conjugate T-DM1 (trastuzumab emtansine) in a critical Phase III clinical trial. While the exact anumbers are not yet available, Roche reports that top-line data from the EMILIA trial

showed patients with HER2+ metastatic breast cancer that were treated with T-DM1 displayed a significant increase in progression free survival, as compared to those treated with lapatinib plus Xeloda. T-DM1 is being developed under a licensing agreement between Roche’s Genentech and Immunogen, and is an exciting example of cutting-edge innovation in antibody-drug conjugate (ADC) development. Early ADCs (such as Seattle Genetics’ Adcetris) delivered chemotherapy directly to cancerous cells, by linking a small molecule chemotherapeutic to an antibody targeted towards a tumor specific marker. In contrast, Roche’s T-DM1 couples ImmunoGen’s cancer killer, DM1, to

Genentech’s hugely successful therapeutic antibody Herceptin. In theory, T-DMI should provide the dual action benefits of Herceptin, which binds to the Human Epidermal Growth Factor Receptor 2 (HER2) expressed on the surface of some breast cancer cells. Herceptin binding to HER2 targets the cancer cells for destruction by the immune system, while simultaneously blocking growth-promoting HER2 signaling within the cell. By linking the anticancer compound DM1 to Herceptin, T-DM1 mounts a multi-pronged attack on breast cancer cells that express the HE R2 receptor (HER2+ breast cancer). This is an important strategy in the fight against breast cancer, as it is a disease in which many cellular pathways upregulate to promote tumor cell survival when another pathway is targeted by a cancer drug. Breast cancer can be molecularly inhomogeneous

between patients – therefore targeting a therapy towards a certain segment of patients (just as T-DM1 and Herceptin treat HER2+ breast cancer patients) encourages the likelihood of a drug’s success within a given population. Roche, Immunogen and Genentech are all proudly touting T-DM1’s early success in the EMILIA trial. However, the improved overall progression free survival data presented is only one of the primary trial endpoints, and likely less important than improved overall survival (which requires more mature data). Genentech should be particularly sensitive to the fact that an improvement in progression free survival is not always enough to warrant drug approval. The UK’s National Institute of Health and Clinical Excellence never approved its blockbuster cancer drug Avastin for the breast cancer indication, and ultimately the FDA withdrew the drug from the US market due a lack of data showing improved overall survival and severe side effects that counteracted the small retardation of disease progression. Avastin was initially approved in the US in 2008 under the FDA’s accelerated approval program, and the FDA may have learned their lesson as they refused to file Genetech’s Biologics License Application for T-DM1 under the same accelerated approval program in 2010. With this early data from the EMILIA trial, Genentech plans to try again and submit a Biologics License Application to the FDA for T-DM1 for treatment of metastatic HER2+ breast cancer later this year. Additionally, Roche plans to submit a Marketing Authorization Application to the European Medicines Agency. All parties involved seem to be optimistic; however, data demonstrating significant improvement in overall survival compared to current treatments for HER2+ metastatic breast cancer will be critical to the approval of T-DM1 by global regulatory and watchdog agencies. If they manage to fulfill this criterion, this collaboration stands to be extremely lucrative, as Herceptin sales amounted to 5.25 billion CHF in 2011. Following a recent epidemic of counterfeit Avastin in the US, and a loss of nearly 18% in Avastin sales attributed to the FDA’s withdrawal of its breast cancer indication, Roche and Genentech could really use a win. The better News is that Genomics is on the Clock. Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is GenNXeix Biotech Semiconductor Sequencing. "Quantum Theory" . NAACP make sure your communities no that genomics is how The Affordable Health Act is going to help all Americans.

Julia Jnedokusheva VP of Gennxeix Medical Practice Management Division

July 5, 2012

---

Press Release New York City, NY GenNXeix World Wide

---

GenNXeix today announced that Julia Jnedokusheva VP of Gennxeix Medical Practice Management Division is over seeing

Sales and Marketing and the release of gloStream gloSuite version 7.0 (gloSuite v7), the next iteration of the company's flagship, integrated electronic medical record

("EMR") and practice management ("PM") solution. Like its predecessor versions, gloSuite v7 is built on Microsoft technology, including Microsoft Office and Microsoft Sharepoint, so users have access to the most powerful and widely-used business technology available anywhere. "With medical practice staff under growing pressures and the point of care evolving, doctors are clamoring for new EMR and PM tools and resources that will help them provide better care and run more efficient enterprises," said Mike Sappington, gloStream's Chief Executive Officer. "gloSuite v7, which incorporates collaboration resources, mobility, and tools to increase productivity, was specifically designed to provide medical professionals with the technology they need to be more productive and treat patients more successfully." There are three important themes that permeate the new gloSuite v7 product offering - community, mobility and productivity: Community. Through the gloCommunity Practice Portal within gloSuite v7, gloStream now offers a unique medium where physicians and other healthcare stakeholders can go to >communicate and collaborate with one another. Physicians and medical staff now have the ability to share best practices, templates and protocols; discuss medical advancements and challenges; and download educational materials, too. The outcome is a community of more active medical practitioners with new tools and resources to offer better care to their patients. These new collaboration and information sources create benefits for doctors and patients alike, and hold significant promise to help decrease overall healthcare costs. Mobility. With the point of care evolving beyond the traditional hospital or clinic, doctors and patients both desire new tools that will aid doctor-patient communication and speed up the healthcare delivery process. gloMobile, which comes with gloSuite v7, is an iPad application that offers doctors and practice staff easy access to patient and practice information anywhere and anytime. Amongst other features, users can view full doctor and resource schedules as well as patient documentation; doctors can send prescriptions electronically; and staff can send tasks to one another. Leveraging gloMobile, doctors can access - and act upon - critical patient information regardless of time of day, or location. Productivity. Medical practices are extraordinarily hectic businesses that desperately need tools to help staff become more productive and efficient. gloSuite v7 incorporates a variety of new resources including direct secure messaging, clinical decision support functionality, and improved billing and collections modules to help practices become better organized and more effective. Leveraging this functionality, medical practice staff can send patient information electronically using secure email, improve decision making using clinical decision support technology, and also enhance back end operations through improved billing and collections modules. The benefit is practice staff who are in control of their time, focused, and much more effective. "As one of the very first EMR and PM solutions that offers secure messaging, mobile access and clinical decision support, gloSuite v7 truly is a unique and powerful product," said Piyush Khanna, gloStream's Chief Information Officer. "The combination of new features and improvements to existing functionality means doctors have access to vital tools they need to improve care Data Portability Promise Doctors have an enormous investment in the patient information they've created and should always have the option to move that data to another system if the need arises. We believe so much in data portability and interoperability we promise that patient information will always be stored in Microsoft-based formats, including Microsoft Word and SQL Server, that are supported by thousands of technology Partners worldwide and easily accessible. Unlike competitive offerings, with gloStream practices always have complete control over all of your patient information and can move that data to other systems, if needed. GenNXeix Announces New gloStream Electronic Medical Records (EMR) Solution Partnership To Serve The Medical Community Sincerely, David Burroughs South East Marketing Director GenNXeix Electronic Health Records